Diabetic Foot Files

In this episode , one of the world’s most influential pioneers in limb preservation, Dr.David Armstrong DPM, MD, PhD Distinguished Professor of Surgery and Neurological Surgery and a Global Leader in limb preservation whose research has fundamentally changed how clinicians approach diabetic foot disease.

Dr. Armstrong shares the personal story that inspired his lifelong mission to prevent amputations, describing two unforgettable patients whose experiences taught him one of medicine’s greatest lessons—that the absence of pain can be more dangerous than pain itself.

Throughout the conversation, he explains why diabetic foot ulcers remain one of the most underestimated complications of diabetes, introduces the revolutionary concept of diabetic foot remission, and discusses why healing an ulcer is only the beginning of lifelong prevention.

Listeners will discover:

Why diabetic foot ulcers are a “silent and sinister syndrome”

The true meaning of diabetic foot remission and why recurrence is expected rather than failure

How annual foot screening could prevent countless amputations worldwide

Why multidisciplinary limb preservation teams reduce both amputations and mortality

The biggest unanswered questions surrounding diabetic foot infection

The future of wearable technology, smart insoles, smart socks, smart scales, and AI-powered home monitoring

How underserved communities can dramatically improve limb salvage with collaboration rather than expensive technology

Why the future of diabetic foot care depends on teamwork, innovation, and earlier intervention

Dr. Armstrong also reflects on the evolution of limb preservation over the past three decades, discusses the rapid advances in digital health and remote monitoring, and shares his vision of a future where preventable diabetic amputations become increasingly rare.

Whether you’re a podiatrist, vascular surgeon, wound care specialist, endocrinologist, nurse, therapist, researcher, student, or someone living with diabetes, this conversation offers invaluable insights from one of the architects of modern diabetic limb salvage.



Key Takeaway:

“Find a friend.” According to Dr. Armstrong, preventing amputations isn’t the work of one specialty—it takes interdisciplinary teams united by one mission: keeping patients walking and living healthier lives.

This episode explains the crucial difference between hypoxia (low oxygen that can trigger repair) and ischemia (lack of blood flow that deprives tissue of oxygen, nutrients, and immune cells), and how diabetes worsens both.

Clinical takeaways: check vascular status with toe pressures and TcPO2 before escalating to advanced wound therapies, and prioritize revascularization when needed to give wounds a real chance to heal.

Dr. G explains how hypoxia‑inducible factor 1 alpha (HIF‑1α) acts as the cell's oxygen sensor and coordinator of wound repair, why diabetes disrupts its signaling, and how that impairment stalls healing in diabetic foot ulcers.

The episode summarizes how researchers measure HIF‑1α, and reviews emerging treatments—HIF stabilizers, gene/RNA therapies, stem cells, engineered scaffolds, and oxygen‑releasing biomaterials—that aim to restore molecular healing pathways and improve limb salvage.

This episode explains how xylazine ("tranq"), a veterinary sedative now found in the illicit drug supply, is causing severe, fast-progressing wounds and infections when mixed with fentanyl.

It reviews the drug's vasoconstrictive effects, wound features (necrosis, deep infection, slow healing), key differences from diabetic foot ulcers, treatment priorities (debridement, antibiotics, advanced wound care), and the need for compassionate, comprehensive care and referral for substance use disorders.

In this episode of Limb Watch Series with Diabetic Foot Files, host interviews Jason Ayers, a wound care RN and inventor of a topical oxygen hydrotherapy kit that combines warmed antimicrobial cleansing solution with localized oxygen bubbles to cleanse and promote healing in chronic wounds, especially diabetic foot ulcers.

Jason explains the origin and prototype development, demonstrates a typical 10–15 minute treatment session, and shares case-study results showing faster cleansing, improved tissue color, reduced drainage and odor, and positive patient feedback.

The discussion covers how the device fits into current debridement tools, safety and infection-control design choices, and the inventor’s vision for broader clinical adoption and training to help prevent amputations and advance limb preservation.